Short CommunicationsSafety and efficacy of electrochemotherapy in a series of patients with nonmetastasized primary or recurrent anorectal malignant melanomaFarricha, Victora; Quaglino, Pietrob; Brizio, Matteob; de Terlizzi, Francescac; Bartolo, Joanaa; Carvalhal, Saraa; Caracò, Corradod; Di Monta, GianlucadAuthor Information aInstituto Portugues de Oncologia de Lisboa Francisco Gentil, Lisboa, Portugal bDepartment of Medical Sciences, dermatologic clinic, University of Turin, Turin cIGEA Biophysics Laboratory, Modena dNational Cancer Institute Fondazione G. Pascale, SSD Chirurgia Melanoma e dei Tumori Cutanei, Naples, Italy Received 31 January 2020 Accepted 29 August 2020 Correspondence to Francesca de Terlizzi, MS, Via Parmenide 10/A, 41012 Carpi (MO), Italy, Tel: +39 3487262522; fax: +39 059 695778; e-mail: [email protected] Melanoma Research: February 2021 - Volume 31 - Issue 1 - p 76-80 doi: 10.1097/CMR.0000000000000699 Buy Metrics Abstract Anorectal malignant melanoma (AMM) is a rare malignant tumor. Surgery remains the gold standard but new adjuvant treatments to allow local sphincter-saving are warranted. Electrochemotherapy (ECT) is an alternative to surgery in selected cohorts of patients. To evaluate safety and efficacy of ECT in a retrospective series of patients with primary or recurrent AMM in terms of local disease control, local progression free and overall survival. Seven primary and one recurrent AMM underwent ECT. Patients were followed at 1 and 2 months and at the longest available follow-up with clinical examination and/or ultrasound. One month after ECT 6/8 (75%) patients showed complete response, 1/8 partial response (12.5%) and 1/8 stable disease (12.5%), confirmed at 2 months. Bleeding stopped in all patients, and pain was absent or mild/moderate in all patients. No serious adverse events were observed. At 1 year of follow-up seven out of eight patients were alive (87.5%), four were disease-free and three were alive with disease. At the longest available follow-up (mean 4.9 ± 2.0 years) five out of eight (62.5%) of patients were still alive. Our study showed that ECT is well tolerated and effective in the treatment of patients with anal melanoma with good local control of disease. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.